|Publication number||US2687367 A|
|Publication date||Aug 24, 1954|
|Filing date||May 5, 1952|
|Priority date||May 5, 1952|
|Publication number||US 2687367 A, US 2687367A, US-A-2687367, US2687367 A, US2687367A|
|Inventors||Burrin Philo L|
|Original Assignee||Lilly Co Eli|
|Export Citation||BiBTeX, EndNote, RefMan|
|Patent Citations (4), Referenced by (17), Classifications (11)|
|External Links: USPTO, USPTO Assignment, Espacenet|
P. l.. BURRIN 2,687,367
FICATION FRAGMENTS Aug. 24, 1954 MEDICINAL TABLET CONTAINING IDENTI Filed May 5, 1952 Patented Aug. 24, 1954 MEDICINAL TABL IDENTIFICATIO ET CONTAINING N FRAGMENTS Philo L. Burrin, Indianapolis, Ind., assigner to Eli Lilly and Company,
corporation of Indiana AApplication May 5, 1952, Serial No. 286,157
. 3 Claims.
This invention relates to a protective identification of ethical drugs such ,asy tablets, capsules and the like and to a method of producing such medications having such protective identification.
In the practice of medicine it is customary, in many instances and for various reasons, to conceal from the patient the name, nature and/or character of the medicament prescribed for the illness being treated. For this reason, the manufacturer of ethical drugs, cooperating with the medical profession, for the most part refrains from placing any mark or indicia on the medicine per se, i. e., upon the tablet, capsule, pill, or the like, the identification of the medicament and brand name being ahxed as by label to a bottle or other container in which such drug items are customarily packaged. This has sever-al disadvantages amongst which is the extreme disadvantage owing from an unscrupulous substitution or palming off of a possibly inferior substitute or unwanted or unprescribed tablet, pill or capsule for the particular ethical drug called for by the prescription.
It is an obj ect of the present invention to provide an ethical drug product such as a, pill, tablet, capsule lor lthe like which is secretively marked so as to be easily identifiable by the ethical drug manufacturer, his agent or representative, the druggist or physician, and yet which is not readily observable and remains relatively secret from the patient.
A further object of this invention is to provide anethical drug i-dentication means of the above character, which is simple, effective, easily accomplished oonformably to present day mass production methods and with but little additional expense.
Other objects of the invention will become apparent from -the following description, appended claims, and accompanying drawings wherein:
Fig. l is an enlarged side elevation, partly in section, of an uncoated medicinal base tablet of the character in which the invention may be embodied, and
Fig. 2 is a View similar the base tablet With the thereover.
The tablet I shown in Fig. 1 is of the usual ellipsoidal shape and of the customary form used generally by the pharmaceutical industry. It will be understood that the representation of a tablet for the embodiment of the invention is for illustrative purposes only and that the invention can as well nd us-e in the secretive identification of to Fig. 1 but showing usual coating applied Indianapolis, Ind., a
capsules, pills and other like items used in preparing medicaments for administration.
Generally speaking, the granulations (indicated by cross section lines .at I I in Figs. 1 and 2) composingr medicinal tablets are of a size ranging from 2000 to 3000 microns. Th-e invention comprises the thorough mixing of innocuous, inert, colored, fragments I 2 of gelatin, methyl cellulose, ethyl cellulose, sucrose or the like and of a size of the order of 250 to 840 microns into the granulation II constituting the tablet compound in such a manner as to yuniformly but randomly disperse the fragments completely and thoroughly throughout the compound. While methyl and/or ethyl cellulose fragments may 'be used, gelatin or sucrose fragments are preferred because the latter are assimilable or metabolizible in the human system. added in relatively small proportions to the total composition, i. e., the quantity of fragments ladded is from one to ten percent of the total composition. Following this the compound, with the colored fragments -thoroughly mixed therein, is compressed in the usual manner into the tablet form illustrated in Figs. 1 and 2 wherein it is observed that theV colored fragments are clearly visible over all surfaces of the base tablet I0 as well as the sectioned portion thereof. Fragments I2 are shown in the illustration as being the primary colors, red, blue and yellow. It will 'be course that any single color or combination of colors may be used and that the above selection is arbitrary and set forth merely for illustrative purposes.
Following the compression of the medicinal compound into tablet form as above described the base tablet I 0 has one or more coatings such applied completely thereover in the usual pensed.
Consequently, the patient that The fragments I2 are vision of the -colored gelatin fragments the pharmaceutical manufacturer or his field representative may readily ascertain whether a substitution or palming ofi of a possibly inferior or unwanted or unprescribed product for the particular manufacturers product has been or is being attempted to be effected as by simply removing a sufficient portion of the coating materials i5, i4, and I3 to expose at least a moderate sized surface portion of the base sectioning or breaking the tablet open to expose its interior. This will expose .the colored fragments to view and their particular size and color combination will readily identify the manufacturers product, Whereas upon applying the same test to a substitute product such fragments will be either entirely absent or not within the proper color combination to identify the product as being supplied by the particular manufacturer.
Hence it will be seen that I have provided by my invention a simple, inexpensive and secretive means of positively giving identification to ethical drugs in `tablet or like form and a method of making such tablets or the like Which is simply, efficiently and economically adaptable to the customary manufacturing methods and techniques employed by the pharmaceutical industry in the manufacture of such items. At the same time, my invention retains the product completely free of any suggestion to the ultimate consumer of the nature and/ or character of the medicament prescribed for any specific illness which is being ltreated thereby meeting the demands of the medical practitioner.
1. As an article of manufacture, a medicinal base tablet having a coating exteriorly thereover and interiorly of said coating having its medicinal granulations uniformly flecked throughout with a dispersion of multi-colored, inert, harmless,
metabolizible, gelatin fragments, said colored fragments having been previously admixed with said granulations and being completely hidden by said coating but becoming readily visible upon removal of a portion of said coating sufficient to Itablet l or by simply expose a relatively small area of the surface of said base tablet or upon breaking said tablet open.
2. As an article of manufacture, a medicinal base tablet compressed of medicinal granules of a size of the order of from 2000 to 3000 microns, said tablet having a 1 to 10 percent proportion of its total composition of colored, inert, innocuous, contrasting colored, metabolizible, gelatin fragments of a size of the order of 250 to 840 microns thoroughly admixed with and uniformly dispersed at random -throughout said medicinal granules before their compression into tablet form, said fragments being visible on all exterior surfaces of the base tablet land on any surface thereof exposed by reason of sectionalizing said tablet, and a coating completely covering said base tablet and said contrasting colored fragments.
3. A medicinal tablet comprising an inner base having a coating applied completely thereover, said base having its medicinal granules thoroughly admixed with a portion of multi-colored, inert, metabolizible, gelatin particles in sufficient proportion With respect to said granule mass that following thorough admixing with said mass and upon being compressed therewith intoA said inner base, said particles are thoroughly and uniformly distributed surf acewise of and interiorly throughout said base, said dispersed, colored particles being completely covered by said coating and becoming readily visible upon breaking said tablet open or upon removal of a portion of said coating suicient to expose a relatively small area of the surface of the said base tablet.
lgeferences Cited in the le of this patent UNITED STATES PA'IENTS Number Name Date 1,134,156 Platen Apr. 6, 1915 1,148,621 Planten Aug. 3, 1915 2,410,110 Taylor Oct. 29, 1946 FOREIGN PATENTS Number Country Date 621,651 Great Britain Apr. 13, 1949
|Cited Patent||Filing date||Publication date||Applicant||Title|
|US1134156 *||Dec 3, 1914||Apr 6, 1915||Hermanus Rolff Planten||Gelatin capsule.|
|US1148621 *||Dec 9, 1914||Aug 3, 1915||Hermanus Rolff Planten||Gelatin capsule.|
|US2410110 *||Jan 14, 1943||Oct 29, 1946||Brewer & Company Inc||Method of making tablets|
|GB621651A *||Title not available|
|Citing Patent||Filing date||Publication date||Applicant||Title|
|US3044938 *||Jul 1, 1955||Jul 17, 1962||Sandoz Chemical Works Inc||Sustained action pharmaceutical tablets|
|US3125490 *||Aug 9, 1961||Mar 17, 1964||Tablet with contrasting indicia and method|
|US3177820 *||Mar 27, 1961||Apr 13, 1965||American Cyanamid Co||Tablet granulation apparatus|
|US4390452 *||Aug 20, 1979||Jun 28, 1983||Minnesota Mining & Manufacturing Company||Microparticles with visual identifying means|
|US4432966 *||Aug 31, 1982||Feb 21, 1984||Roussel-Uclaf||Compressed tablets for disintegration in the colon comprising an active ingredient containing nucleus coated with a first layer containing microcrystalline cellulose which is coated with an enteric organic polymer coating|
|US4457907 *||Aug 5, 1982||Jul 3, 1984||Clear Lake Development Group||Composition and method for protecting a therapeutic drug|
|US4661367 *||Sep 27, 1985||Apr 28, 1987||Imperial Chemical Industries Plc||Process for the manufacture of colored intagliated articles|
|US5002775 *||Mar 4, 1983||Mar 26, 1991||Sumitomo Chemical Company, Limited||Tablets having clear impressed marks and method for making same|
|US5283065 *||Mar 23, 1992||Feb 1, 1994||American Cyanamid Company||Controlled release pharmaceutical compositions from spherical granules in tabletted oral dosage unit form|
|US5431918 *||Oct 30, 1992||Jul 11, 1995||Soremartec S.A.||Breath mint configuration|
|US7720254||Mar 13, 2007||May 18, 2010||Smi Holdings, Inc.||Automatic microparticle mark reader|
|US7831042||Mar 13, 2007||Nov 9, 2010||Smi Holdings, Inc.||Three-dimensional authentication of microparticle mark|
|US7885428||Dec 18, 2009||Feb 8, 2011||Smi Holdings, Inc.||Automatic microparticle mark reader|
|US8033450||Mar 13, 2007||Oct 11, 2011||Smi Holdings, Inc.||Expression codes for microparticle marks based on signature strings|
|US8223964||Oct 6, 2010||Jul 17, 2012||Smi Holdings, Inc.||Three-dimensional authentication of mircoparticle mark|
|US8888005||May 31, 2013||Nov 18, 2014||David Prokop||Uniquely identifiable drug dosage form units|
|US20060037222 *||Dec 2, 2002||Feb 23, 2006||Dan Hunt||Taggants for products and method of taggant identification|
|U.S. Classification||424/10.3, 424/465, 424/467, 424/472, 424/470|
|International Classification||A61K9/20, A61K9/28|
|Cooperative Classification||A61K9/28, A61K9/2072|
|European Classification||A61K9/28, A61K9/20K|